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Abstract
Metformin has been proven beneficial for the first-line
treatment of type 2 diabetic mellitus (T2DM) due to its efficacy
and low adverse effect profile. Current US guidelines do not
address the use of early intensive insulin use in T2DM.
Treatment plans are slowly adjusted over the months until the
A1C goal is met. Insulin is initiated several years after the time
of T2DM diagnosis and utilized as second-line therapy. Dual
therapy of insulin and metformin have shown regression of
T2DM in certain patient populations. However, the linear
relationship between diabetes and cardiovascular disease does
not show greater improvement with dual aggressive therapy.
The ACCORD study found intensive insulin use has led to an
increase in mortality in diabetic patients. The purpose of this
literature review is to gather data using clinical studies and
peer-reviewed articles that can determine if metformin and
insulin should be used intensively to lower A1C aggressively
compared to using standard therapy of metformin to decrease
the long-term effects of abnormal A1C levels.
Keywords: insulin, metformin, dual therapy, regression,
mortality, A1C, intensive insulin therapy, guidelines

Statement of the Problem
• The average time for insulin initiation is 11.5 years (Cohen et
al., 2016). The importance of maintaining or achieving A1C
goal is delaying the progression of microvascular,
macrovascular, and other complications associated with
T2DM.
• Despite evidence from landmark clinical trials and
recommendations in published guidance, glycemic control is
often poor for patients in clinical practice and insulin therapy
can be delayed or not optimized (Cohen et al., 2016).
• CVD is a major reason for death among diabetics due to the
extended period of abnormally high A1C.
• Current treatment guidelines do not have an option to treat
patients with intensive insulin therapy.

Literature Review
• Remission rates after one year post therapy are found to be
higher in the insulin group compared to the oral
antihyperglycemic agents (p = 0.0012) (Cheng et al., 2008).

• The ACCORD study showed increase mortality rate due to
intensive insulin therapy. Intensive insulin therapy was shown
to have some benefit by reducing the risk of retinopathy and
microalbuminuria (Genuth and Ismail- Beigi, 2012).
• Three months after stopping intensive insulin therapy 66.2% of
patients were in drug-free remission. The remission rate after
six months 58.9%, twelve months 46.3%, and 42.1% after 24
months. (Kramer, Retnakaran, and Zinman, 2013)
• Short-term intensive insulin with metformin suggests remission
rates of 51.1% for the continuous subcutaneous insulin infusion
and 44.9% for the multiple daily injections (Weng et al., 2017).

Discussion
• In the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial, intensive glycemic control significantly
reduced the risk and/or progression of retinopathy,
nephropathy, and neuropathy (ADA, 2009)
• The Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study had a premature stop due to the 22%
increase in the mortality rate of intensively treated T2DM
patients

Research Questions
• Does metformin at time of therapeutic treatment have more
benefit then insulin in type 2 diabetics to control A1C?
Alam, I. (2019). Management of Diabetes Treat to Target Approach. Lady Reading Hospital. Retrieved from
http://slideplayer.com/slide/242222/

• Is there a benefit of early intensive insulin therapy when added
to metformin in type 2 diabetic patients to control their A1C?

• Reversing β-cell dysfunction can lead to remission after one
year in 44% of type 2 diabetic patients that have been treated
with intensive insulin therapy (Ferrannini et al., 2018).

Chamberlain, J., Herman, W., Leal, S., Rhinehart, A., Shubrook, J., Skolnik, N., Rastogi, R., (2017). Pharmacologic therapy
for type 2 diabetes: Synopsis of the 2017 American Diabetes Association standards of medical care in diabetes. Annals of
Internal Medicine. 166(8) 572-578. http://doi.org/10.7326/M16-2937

• Patients that could benefit from dual metformin and
intensive insulin therapy are younger adults that have
new onset of T2DM and lower baseline A1C

• The Center for Disease Control and Prevention (CDC)
estimates 9.4% of the U.S. population has T2DM, another 33%
of adults have prediabetes.

• 7 in 10 people
with diabetes
over the age of
65 will die of
some type of
heart disease
(CDC, 2017).

• Metformin used in dual therapy with insulin should be
applied to a patient profile that meets current ADA
guidelines.

• Insulin has less risk of hypoglycemia and weight gain when
used with metformin. Insulin dosage is also decreased using
combination therapy (Halapy et al., 2012).

Introduction

• For every one
percent
increase in
A1C, a
patients risk
of CVD event
increases by
16%.

Applicability to Clinical Practice

• The United Kingdom Prospective Diabetes Study (UKPDS)
data found no increase in mortality from intensive insulin
therapy
• One of the downfalls of metformin is the progressive loss of
efficacy as expressed in Ferrannini et al. (2018)
• Providers are more apprehensive of starting insulin than the
patients are (Halapy et al. 2012).

• What is the safety profile of metformin and insulin as
monotherapy and dual-therapy for type 2 diabetics?

• Insulin is often withheld from treatment regimens because of
its perceived negative impact on the patient’s quality of life
(QOL) (Weng et al. 2017).

• What are the long-term benefits of starting intensive insulin
early in the treatment of type 2 diabetes?

• Initiation of drug therapy should consider the clinical
characteristics of the patient profile, efficacy of the drug, side
effects, and cost.
• The ideal patient for receiving intensive therapy are lower
fasting plasma glucose and a higher BMI at baseline (Kramer,
2013)
• Insulin has been used in short course studies such as Opsteen
et al. (2010) and Ferrannini et al. (2018) to induce diabetic
remission

• The patients that should avoid or follow closely when
intensive insulin therapy are older adults (> 55 years
old), have had CVD or other risk factors for CVD, and
have had T2DM for several years
• Start insulin therapy shortly after the diagnosis of
T2DM when starting dual therapy with metformin.
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